The goal of this activity is for learners to be better able to describe the mechanism of action of CAR T-cell therapy, the rationale for applying this therapy in neurological autoimmune disease, and the latest clinical trial evidence supporting the use of these therapies in diseases such as multiple sclerosis (MS) and myasthenia gravis (MG).
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1001590
- Start Date: 2024-09-18 05:00:00
- End Date: 2024-09-18 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Kyverna Therapeutics, Inc. - Amount: 183519.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest